Related Experiment Videos
A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats
Kaitlin E Browman1, Peter Curzon, Jia Bao Pan
1Neuroscience Research, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064-6115, USA. kaitlin.e.browman@abbott.com
Pharmacology, Biochemistry, and Behavior
|September 13, 2005
Summary
A new drug, A-412997, shows promise for enhancing cognition by targeting dopamine D4 receptors. This selective agonist demonstrated effectiveness in rat models relevant to attention deficit hyperactivity disorder and short-term memory.
Area of Science:
- Neuroscience
- Pharmacology
- Cognitive Science
Background:
- The dopamine D4 receptor's role in central nervous system functions remains incompletely understood.
- Development of selective pharmacological tools is crucial for investigating receptor-specific functions.
Purpose of the Study:
- To evaluate the cognitive-enhancing potential of a novel, highly selective dopamine D4 receptor agonist, A-412997.
- To compare the efficacy of A-412997 with less selective dopamine D4 receptor agonists (PD168077, CP226269) in preclinical models.
Main Methods:
- Utilized rat models for attention deficit hyperactivity disorder (ADHD) using a 5-trial repeated acquisition inhibitory avoidance task.
- Assessed short-term memory using a Social Recognition task in rats.
- Administered A-412997, PD168077, and CP226269 in dose-dependent studies.
Main Results:
- A-412997 demonstrated significant, dose-dependent cognitive enhancement in both ADHD and short-term memory models.
- PD168077 showed improvements in social recognition but not consistently in the inhibitory avoidance task.
- CP226269 significantly enhanced performance in the 5-trial inhibitory avoidance model.
Conclusions:
- The findings support a significant role for the dopamine D4 receptor subtype in cognitive processes.
- A-412997 represents a valuable pharmacological tool for further research into dopamine D4 receptor functions.
- Selective targeting of dopamine D4 receptors may offer therapeutic potential for cognitive deficits.